Clene (CLNN) stock was up around 3% today. Recent earnings report indicated $0.42 in EPS and $110K in revenue, beating estimates. CEO, Rob Etherington, says that the biopharmaceutical company focuses on neurodegenerative diseases. What are the plans for the company's future growth, and how will the CLNN stock price continue to perform?
18 Nov 2021
Morning Trade Live
14 Nov 2022
Trading 360
28 Sep 2022
Market On Close
28 Sep 2022
Market On Close
03 Oct 2022
Morning Trade Live
07 Nov 2022
The Watch List
14 Nov 2022